Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 8 | 2023 | 396 | 1.890 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2024 | 75 | 1.820 |
Why?
|
| Electrocardiography | 12 | 2022 | 637 | 1.510 |
Why?
|
| Heart Failure | 11 | 2024 | 761 | 1.150 |
Why?
|
| Syncope | 2 | 2022 | 27 | 0.990 |
Why?
|
| Risk Assessment | 13 | 2024 | 1469 | 0.870 |
Why?
|
| Defibrillators, Implantable | 5 | 2021 | 37 | 0.870 |
Why?
|
| Coronary Disease | 2 | 2024 | 217 | 0.830 |
Why?
|
| Cryosurgery | 1 | 2023 | 23 | 0.780 |
Why?
|
| Risk Factors | 18 | 2024 | 4001 | 0.740 |
Why?
|
| C-Reactive Protein | 3 | 2014 | 240 | 0.730 |
Why?
|
| Stroke | 6 | 2022 | 610 | 0.730 |
Why?
|
| Humans | 47 | 2024 | 32952 | 0.690 |
Why?
|
| Atherosclerosis | 2 | 2024 | 801 | 0.630 |
Why?
|
| Catheter Ablation | 1 | 2021 | 114 | 0.620 |
Why?
|
| Middle Aged | 26 | 2024 | 12202 | 0.590 |
Why?
|
| Heart | 2 | 2020 | 185 | 0.590 |
Why?
|
| Stroke Volume | 7 | 2024 | 421 | 0.580 |
Why?
|
| Male | 32 | 2024 | 19743 | 0.540 |
Why?
|
| Exercise Therapy | 2 | 2012 | 282 | 0.520 |
Why?
|
| Aged | 24 | 2024 | 10624 | 0.510 |
Why?
|
| Female | 31 | 2024 | 20363 | 0.480 |
Why?
|
| Hypertension | 4 | 2017 | 983 | 0.480 |
Why?
|
| Prospective Studies | 12 | 2022 | 2338 | 0.420 |
Why?
|
| Coronary Artery Disease | 2 | 2021 | 416 | 0.410 |
Why?
|
| Hospitalization | 4 | 2024 | 495 | 0.400 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 765 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 298 | 0.390 |
Why?
|
| Kidney | 1 | 2016 | 523 | 0.370 |
Why?
|
| Heart Ventricles | 4 | 2021 | 146 | 0.360 |
Why?
|
| Earthquakes | 1 | 2011 | 2 | 0.350 |
Why?
|
| Inflammation | 2 | 2021 | 542 | 0.350 |
Why?
|
| Disasters | 1 | 2011 | 9 | 0.350 |
Why?
|
| Echocardiography | 7 | 2018 | 191 | 0.350 |
Why?
|
| International Cooperation | 1 | 2011 | 30 | 0.350 |
Why?
|
| Ventricular Function, Left | 6 | 2022 | 268 | 0.350 |
Why?
|
| Interleukin-6 | 2 | 2009 | 241 | 0.340 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2017 | 172 | 0.330 |
Why?
|
| Incidence | 7 | 2024 | 1246 | 0.320 |
Why?
|
| United States | 9 | 2022 | 4132 | 0.310 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2009 | 8 | 0.310 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 26 | 0.310 |
Why?
|
| Life Style | 1 | 2012 | 409 | 0.300 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2009 | 10 | 0.300 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 185 | 0.290 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 102 | 0.290 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 105 | 0.290 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 89 | 0.290 |
Why?
|
| Heart Rate | 3 | 2020 | 345 | 0.280 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 67 | 0.280 |
Why?
|
| Vascular Diseases | 1 | 2008 | 68 | 0.270 |
Why?
|
| Japan | 3 | 2012 | 19 | 0.270 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 156 | 0.260 |
Why?
|
| Aortic Valve Stenosis | 3 | 2017 | 41 | 0.260 |
Why?
|
| Candidiasis | 1 | 2006 | 6 | 0.250 |
Why?
|
| Treatment Outcome | 5 | 2023 | 3460 | 0.250 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 7 | 0.250 |
Why?
|
| Malaria | 1 | 2006 | 13 | 0.250 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2020 | 27 | 0.250 |
Why?
|
| Abscess | 1 | 2006 | 27 | 0.250 |
Why?
|
| African Americans | 4 | 2020 | 1425 | 0.240 |
Why?
|
| Anticoagulants | 3 | 2022 | 136 | 0.240 |
Why?
|
| Prognosis | 7 | 2022 | 1547 | 0.230 |
Why?
|
| Mississippi | 6 | 2024 | 35 | 0.230 |
Why?
|
| Exercise | 3 | 2021 | 687 | 0.230 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 355 | 0.220 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2021 | 16 | 0.210 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2017 | 121 | 0.210 |
Why?
|
| Ankle Brachial Index | 1 | 2024 | 40 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2287 | 0.200 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 1152 | 0.200 |
Why?
|
| Myocardium | 3 | 2018 | 192 | 0.190 |
Why?
|
| Smoking Cessation | 1 | 2024 | 216 | 0.180 |
Why?
|
| Desmoglein 2 | 1 | 2021 | 1 | 0.180 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 2 | 0.180 |
Why?
|
| Bisoprolol | 1 | 2021 | 2 | 0.180 |
Why?
|
| Flecainide | 1 | 2021 | 2 | 0.180 |
Why?
|
| Ventricular Remodeling | 2 | 2022 | 67 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 27 | 0.170 |
Why?
|
| HIV Infections | 1 | 2006 | 424 | 0.170 |
Why?
|
| Tachycardia | 2 | 2012 | 6 | 0.170 |
Why?
|
| Adult | 10 | 2024 | 9586 | 0.160 |
Why?
|
| Hemorrhage | 3 | 2022 | 107 | 0.160 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 59 | 0.160 |
Why?
|
| Ventricular Premature Complexes | 1 | 2020 | 18 | 0.160 |
Why?
|
| Prevalence | 3 | 2020 | 1002 | 0.160 |
Why?
|
| Atrial Premature Complexes | 1 | 2020 | 19 | 0.160 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 44 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 28 | 0.160 |
Why?
|
| Time Factors | 5 | 2024 | 2195 | 0.160 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 116 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2019 | 17 | 0.150 |
Why?
|
| Heart Conduction System | 1 | 2020 | 78 | 0.150 |
Why?
|
| Body Size | 1 | 2019 | 34 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4057 | 0.150 |
Why?
|
| European Continental Ancestry Group | 2 | 2020 | 1163 | 0.150 |
Why?
|
| Neck | 1 | 2019 | 31 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 1852 | 0.140 |
Why?
|
| Leptin | 1 | 2018 | 73 | 0.140 |
Why?
|
| Osteoprotegerin | 1 | 2017 | 2 | 0.140 |
Why?
|
| Atrioventricular Block | 1 | 2017 | 5 | 0.130 |
Why?
|
| Bradycardia | 1 | 2017 | 18 | 0.130 |
Why?
|
| Heart Block | 1 | 2017 | 10 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 22 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 19 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 66 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2020 | 469 | 0.130 |
Why?
|
| Rest | 1 | 2017 | 52 | 0.130 |
Why?
|
| Aorta | 1 | 2017 | 127 | 0.130 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2016 | 4 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 107 | 0.120 |
Why?
|
| Creatinine | 1 | 2016 | 199 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2016 | 57 | 0.120 |
Why?
|
| Cause of Death | 2 | 2017 | 240 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 310 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 894 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 780 | 0.110 |
Why?
|
| Survival Rate | 2 | 2017 | 895 | 0.100 |
Why?
|
| Blood Pressure | 3 | 2020 | 867 | 0.100 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2013 | 13 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2013 | 16 | 0.100 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 2 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 526 | 0.090 |
Why?
|
| Dehydration | 1 | 2012 | 9 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2011 | 3 | 0.090 |
Why?
|
| Telemetry | 1 | 2011 | 29 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 541 | 0.090 |
Why?
|
| Recurrence | 1 | 2012 | 282 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2017 | 3708 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2011 | 288 | 0.080 |
Why?
|
| Heart Atria | 1 | 2011 | 79 | 0.080 |
Why?
|
| Sex Factors | 3 | 2019 | 681 | 0.080 |
Why?
|
| Patient Participation | 2 | 2022 | 87 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1179 | 0.080 |
Why?
|
| Biological Markers | 1 | 2009 | 2 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2009 | 45 | 0.080 |
Why?
|
| Disease Progression | 1 | 2011 | 594 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2009 | 59 | 0.070 |
Why?
|
| Animals, Genetically Modified | 1 | 2009 | 68 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2009 | 111 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2009 | 162 | 0.070 |
Why?
|
| Rabbits | 1 | 2009 | 193 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 128 | 0.070 |
Why?
|
| Exercise Test | 1 | 2009 | 225 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2008 | 70 | 0.070 |
Why?
|
| Quality of Life | 1 | 2013 | 976 | 0.070 |
Why?
|
| Gene Expression | 1 | 2009 | 336 | 0.070 |
Why?
|
| Actomyosin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Genotype | 1 | 2009 | 731 | 0.070 |
Why?
|
| New York | 1 | 2006 | 23 | 0.060 |
Why?
|
| Remission Induction | 1 | 2006 | 86 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2006 | 20 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 74 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 1202 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 60 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 445 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 682 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1015 | 0.060 |
Why?
|
| Ultrasonic Therapy | 1 | 2005 | 4 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2005 | 60 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2005 | 39 | 0.050 |
Why?
|
| Warfarin | 1 | 2022 | 34 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2021 | 17 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2021 | 51 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 189 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 413 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 98 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 281 | 0.040 |
Why?
|
| Animals | 2 | 2009 | 7598 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2019 | 28 | 0.040 |
Why?
|
| Triglycerides | 1 | 2020 | 229 | 0.040 |
Why?
|
| Action Potentials | 1 | 2020 | 186 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 141 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2020 | 236 | 0.040 |
Why?
|
| Insulin | 1 | 2020 | 369 | 0.030 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2017 | 1 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 220 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2020 | 495 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2017 | 13 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 98 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 41 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 20 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2017 | 67 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 151 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 48 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 34 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 74 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 101 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 326 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 77 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2017 | 134 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2017 | 183 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 573 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 241 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2017 | 145 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 908 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 403 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 880 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 882 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1580 | 0.020 |
Why?
|
| Cardiography, Impedance | 1 | 2012 | 5 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2013 | 162 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 258 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 195 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1083 | 0.020 |
Why?
|
| Sarcomeres | 1 | 2007 | 4 | 0.020 |
Why?
|
| Myosins | 1 | 2007 | 11 | 0.020 |
Why?
|
| Elasticity | 1 | 2007 | 38 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 51 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 157 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 206 | 0.020 |
Why?
|
| Protein Binding | 1 | 2007 | 201 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2007 | 224 | 0.020 |
Why?
|
| Transducers | 1 | 2005 | 13 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 392 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 2005 | 10 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 108 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 526 | 0.010 |
Why?
|